Inactive Instrument

Cambrex Corporation

CBM

Cambrex to Announce Fourth Quarter 2015 Financial Results on February 9, 2016

February 05, 2016 at 03:48 pm EST

EAST RUTHERFORD, N.J., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) announced that fourth quarter 2015 financial results will be released on Tuesday, February 9, 2016 before the market opens.

The Company will host a conference call to discuss the financial results.

Fourth Quarter 2015 Earnings Conference Call

When: Tuesday, February 9, 2016 at 8:30 a.m. Eastern Time

Dial-in: 1-800-905-0392 for U.S.
1-785-830-1913 for International
Passcode: 2549872

Dial-in Replay: 1-888-203-1112 for U.S.
                                    1-719-457-0820 for International
                                    Passcode: 2549872
                                    Available through Tuesday, February 16, 2016

Webcast: www.cambrex.com

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.

Contact: Stephanie LaFiura
             Investor Relations Associate
Phone:   201.804.3037
Email:    stephanie.lafiura@cambrex.com

Latest news about Cambrex Corporation

Noramco, Inc. acquired Drug Product Business Unit of Cambrex Corporation.	Nov. 01	CI
Noramco, Inc. acquired Halo Pharma, Inc. from Cambrex Corporation.	Nov. 01	CI
Cambrex Announces Grand Opening of New First Stability Storage Commercial Agreement	23-05-31	CI
Cambrex Opens New Stability Storage Facility in Belgium	23-04-04	CI
Cambrex Corporation completed the acquisition of Snapdragon Chemistry, Inc.	23-01-17	CI
Cambrex Corporation entered into a definitive agreement to acquire Snapdragon Chemistry, Inc.	22-11-20	CI
Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa	22-10-27	CI
Cambrex Corporation Announces Stability Storage Expansions in Ireland and Belgium	22-10-04	CI
Cambrex Completes First Phase of $30 Million Capacity Expansion Project in High Point, North Carolina	22-09-01	CI
Cambrex Corporation acquired Q1 Scientific Limited.	22-05-31	CI
Cambrex Completes Large-Scale US API Expansion	22-04-12	CI
Cambrex Corporation Expands Biopharmaceutical Services Business	22-03-01	CI
Cambrex to Invest $30 Million to Expand Manufacturing Center of Excellence At High Point, NC Facility	21-10-07	CI
Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar	21-06-23	CI
Cambrex Introduces New Kilogram-Scale Gmp Manufacturing Capabilities At Tallinn, Estonia Facility	21-05-26	CI
Cambrex Expands Analytical Services Capabilities at Longmont, Colorado, Facility	21-05-05	CI
Cambrex to Invest $50 Million to Expand Multipurpose Large-Scale Manufacturing Capabilities in the U.S	20-11-17	CI
Cambrex Completes Major Expansion of Solid Form Screening Facility in Edinburgh	20-10-12	CI
Cambrex Increases Flexible Manufacturing Capacity at Karlskoga, Sweden Facility	20-07-01	CI
Cambrex Appoints Thomas Loewald as Member of the Board of Directors Effective September 7, 2020	20-06-18	CI
Cambrex Appoints Thomas Loewald as Chief Executive Officer Effective September 7, 2020	20-06-18	CI
Cambrex Announces Management Changes	20-06-02	CI
Cambrex Announces Board Changes	20-06-02	CI
Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility	20-04-07	CI
Cambrex Appoints Troy Player as President, Early Stage Development and Testing	20-03-31	CI

Chart Cambrex Corporation

Duration

Period

More charts

Company Profile

Cambrex Corporation (Cambrex) is a United States-based small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development and manufacture of small molecule therapeutics. The Company offers a range of specialist drug substance technologies and capabilities including biocatalysis, continuous flow, controlled substances, solid state science, material characterization and potent application program interface. In addition, it also supports conventional dosage forms including oral solids, semi-solids and liquids and has the capabilities to manufacture specialist dosage forms such as modified-release, fixed dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile and non-sterile ointments.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals